Paul Tudor Jones Aurinia Pharmaceuticals Inc. Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.93 - $9.31 $73,723 - $139,221	14,954 New	14,954 $74,000
Q3 2023 Nov 15, 2023	BUY	$7.77 - $12.27 $105,151 - $166,049	13,533 New	13,533 $105,000
Q1 2023 May 15, 2023	BUY	$5.94 - $11.27 $380,831 - $722,553	64,113 Added 153.24%	105,952 $1.16 Million
Q4 2022 Feb 14, 2023	BUY	$4.11 - $8.14 $171,958 - $340,569	41,839 New	41,839 $181,000
Q2 2022 Aug 15, 2022	BUY	$8.95 - $12.8 $558,202 - $798,323	62,369 New	62,369 $627,000
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $313,318 - $700,836	-31,176 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $269,829 - $502,022	15,176 Added 94.85%	31,176 $713,000
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $174,880 - $376,800	16,000 New	16,000 $354,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.